Abstract
The occurrence of a plaque-dependent inflammation in Alzheimers disease has been extensively documented in both human specimens and transgenic models of the disease. Since insoluble plaques are present in AD patients from early preclinical stages of the pathology, the point at which neuroinflammation first occurs in the progression of the AD pathology is still unknown. In this review we discuss the clinical and experimental evidence for the occurrence of inflammation in preclinical, asymptomatic phases of the progression of the AD pathology. In particular, we discuss the evidence from different transgenic models suggesting that a pro-inflammatory process might even be initiated prior to plaque deposition. The factors responsible for the early, pre-plaque inflammation are reviewed, with particular emphasis on the role of soluble Aβ-oligomers. Furthermore, we analyze the consequences of the microglial activation and the deregulation of NGF metabolism, in the context of the earliest amyloid pathology. Finally, we propose MMP-9 as a promising biomarker for signalling early stages of an ongoing CNS inflammation.
Keywords: Preclinical Alzheimer's disease, Aβ oligomers, inflammation, transgenic mice, NGF, MMP-9
Current Alzheimer Research
Title: Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?
Volume: 8 Issue: 2
Author(s): M. T. Ferretti and A. C. Cuello
Affiliation:
Keywords: Preclinical Alzheimer's disease, Aβ oligomers, inflammation, transgenic mice, NGF, MMP-9
Abstract: The occurrence of a plaque-dependent inflammation in Alzheimers disease has been extensively documented in both human specimens and transgenic models of the disease. Since insoluble plaques are present in AD patients from early preclinical stages of the pathology, the point at which neuroinflammation first occurs in the progression of the AD pathology is still unknown. In this review we discuss the clinical and experimental evidence for the occurrence of inflammation in preclinical, asymptomatic phases of the progression of the AD pathology. In particular, we discuss the evidence from different transgenic models suggesting that a pro-inflammatory process might even be initiated prior to plaque deposition. The factors responsible for the early, pre-plaque inflammation are reviewed, with particular emphasis on the role of soluble Aβ-oligomers. Furthermore, we analyze the consequences of the microglial activation and the deregulation of NGF metabolism, in the context of the earliest amyloid pathology. Finally, we propose MMP-9 as a promising biomarker for signalling early stages of an ongoing CNS inflammation.
Export Options
About this article
Cite this article as:
T. Ferretti M. and C. Cuello A., Does a Pro-Inflammatory Process Precede Alzheimers Disease and Mild Cognitive Impairment?, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795255982
DOI https://dx.doi.org/10.2174/156720511795255982 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biomarkers of Alzheimer's Disease Risk in Peripheral Tissues; Focus on Buccal Cells
Current Alzheimer Research Molecular Basis of Inflammation and Insulin Resistance in Obesity
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Identification of Novel Biomarker Candidates by Differential Peptidomics Analysis of Cerebrospinal Fluid in Alzheimers Disease
Combinatorial Chemistry & High Throughput Screening Validity of Oxygen-Ozone Therapy as Integrated Medication Form in Chronic Inflammatory Diseases
Cardiovascular & Hematological Disorders-Drug Targets Glutamate Receptors as Therapeutic Targets for Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Ubiquitin-Proteasome Pathway Components as Therapeutic Targets for CNS Maladies
Current Pharmaceutical Design Lentiviral Vector-Based Models of Amyloid Pathology: From Cells to Animals
Current Alzheimer Research A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design Mild Cognitive Impairment: Advantages of a Comprehensive Neuropsychological Assessment
Current Alzheimer Research C-terminus of Hsp70 Interacting Protein (CHIP) and Neurodegeneration: Lessons from the Bench and Bedside
Current Neuropharmacology Substrates and Inhibitors of Human Multidrug Resistance Associated Proteins and the Implications in Drug Development
Current Medicinal Chemistry Mechanisms of Neurodegeration in Type 2 Diabetes and the Neuroprotective Potential of Dipeptidyl Peptidase 4 Inhibitors
Current Medicinal Chemistry Reliability of the Alzheimer’s Disease Assessment Scale (ADAS-Cog) in longitudinal Studies
Current Alzheimer Research Indole Alkaloids and Semisynthetic Indole Derivatives as Multifunctional Scaffolds Aiming the Inhibition of Enzymes Related to Neurodegenerative Diseases – A Focus on Psychotria L. Genus
Current Topics in Medicinal Chemistry Cell Therapy for Stroke: Emphasis on Optimizing Safety and Efficacy Profile of Endothelial Progenitor Cells
Current Pharmaceutical Design Pharmacologic Strategies for Suppression of Lipid Peroxidation in Neurodegeneration
Current Neuropharmacology Estimation of Familial Combined Hyperlipoproteinemia Prevalence in a Large Rural Population: The Brisighella Heart Study
Vascular Disease Prevention (Discontinued) Antioxidant Properties of Nitric Oxide in Cellular Physiological and Pathophysiological Mechanisms. The Implications of Biological Balance between NO and Oxidative Stress
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Modulation of GABAA Receptors by Natural Products and the Development of Novel Synthetic Ligands for the Benzodiazepine Binding Site
Current Drug Targets Glycyrrhizic Acid Ameliorates Cognitive Impairment in a Rat Model of Vascular Dementia Associated with Oxidative Damage and Inhibition of Voltage-Gated Sodium Channels
CNS & Neurological Disorders - Drug Targets